Literature DB >> 30606674

Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors.

Yan-Ting Wang1, Tian-Qi Shi2, Hai-Liang Zhu3, Chang-Hong Liu4.   

Abstract

Tubulin-targeting drugs have increasingly become the focus of anticancer drugs research. Twenty-five novel benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives were synthesized and evaluated for bioactivity as potential tubulin polymerization inhibitors. Among them, compound 30 showed the most excellent inhibition against tubulin assembly (IC50 = 1.52 μM) and in vitro growth inhibitory activity against a panel of four human cancer cell lines (IC50 = 0.15, 0.21, 0.33 and 0.17 μM, respectively for A549, Hela, HepG2 and MCF-7). It could also validly induce A549 cell apoptosis, cause cell cycle arrest in G2/M phase and disrupt the cellular microtubule network. These results, along with molecular docking data, provided an important basis for further optimization of compound 30 as a potential anticancer agent.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Apoptosis; Benzimidazole; Benzsulfamide; Inhibition; Molecular docking; Pyrazole; Tubulin

Year:  2018        PMID: 30606674     DOI: 10.1016/j.bmc.2018.12.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Design, synthesis, and biological evaluation of novel 5,6,7-trimethoxy quinolines as potential anticancer agents and tubulin polymerization inhibitors.

Authors:  Salimeh Mirzaei; Farhad Eisvand; Farzin Hadizadeh; Fatemeh Mosaffa; Razieh Ghodsi
Journal:  Iran J Basic Med Sci       Date:  2020-12       Impact factor: 2.699

Review 2.  A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization.

Authors:  Oluwakemi Ebenezer; Michael Shapi; Jack A Tuszynski
Journal:  Int J Mol Sci       Date:  2022-04-04       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.